Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype

被引:77
|
作者
Fornacon-Wood, Isabella [1 ]
Faivre-Finn, Corinne [1 ,2 ]
O'Connor, James P. B. [1 ,3 ]
Price, Gareth J. [1 ]
机构
[1] Univ Manchester, Div Canc Sci, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Fdn Trust, Dept Radiat Oncol, Manchester, Lancs, England
[3] Christie Hosp NHS Fdn Trust, Dept Radiol, Manchester, Lancs, England
关键词
Radiomics; Imaging biomarkers; Lung cancer; Personalized medicine; INTEROBSERVER DELINEATION VARIABILITY; LYMPH-NODE METASTASIS; FEATURE STABILITY; PATHOLOGICAL RESPONSE; HISTOLOGIC SUBTYPE; RADIATION-THERAPY; CT IMAGES; STAGE I; FEATURES; PREDICTION;
D O I
10.1016/j.lungcan.2020.05.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiomics has become a popular image analysis method in the last few years. Its key hypothesis is that medical images harbor biological, prognostic and predictive information that is not revealed upon visual inspection. In contrast to previous work with a priori defined imaging biomarkers, radiomics instead calculates image features at scale and uses statistical methods to identify those most strongly associated to outcome. This builds on years of research into computer aided diagnosis and pattern recognition. While the potential of radiomics to aid personalized medicine is widely recognized, several technical limitations exist which hinder biomarker translation. Aspects of the radiomic workflow lack repeatability or reproducibility under particular circumstances, which is a key requirement for the translation of imaging biomarkers into clinical practice. One of the most commonly studied uses of radiomics is for personalized medicine applications in Non-Small Cell Lung Cancer (NSCLC). In this review, we summarize reported methodological limitations in CT based radiomic analyses together with suggested solutions. We then evaluate the current NSCLC radiomics literature to assess the risk associated with accepting the published conclusions with respect to these limitations. We review different complementary scoring systems and initiatives that can be used to critically appraise data from radiomics studies. Wider awareness should improve the quality of ongoing and future radiomics studies and advance their potential as clinically relevant biomarkers for personalized medicine in patients with NSCLC.
引用
收藏
页码:197 / 208
页数:12
相关论文
共 50 条
  • [41] Single anesthetic event for lung cancer diagnosis and treatment: hype or hope for the future?
    Nguyen, Sean H.
    Rao, Madhuri
    MINI-INVASIVE SURGERY, 2025, 9
  • [42] Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality
    Jean-François Morère
    Targeted Oncology, 2010, 5 : 229 - 230
  • [45] Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
    Mamdani, Hirva
    Jalal, Shadia, I
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [46] Hope without hype: EML4-ALK inhibition for treatment of lung cancer
    Govindan, Ramaswamy
    LANCET ONCOLOGY, 2011, 12 (11): : 983 - 984
  • [47] Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: Hope or Hype?
    Zeng, Haiyan
    Yuan, Shuanghu
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34) : 3431 - +
  • [48] Radiomics and artificial intelligence for precision medicine in lung cancer treatment
    Chen, Mitchell
    Copley, Susan J.
    Viola, Patrizia
    Lu, Haonan
    Aboagye, Eric O.
    SEMINARS IN CANCER BIOLOGY, 2023, 93 : 97 - 113
  • [49] Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine
    Tunali, Ilke
    Gillies, Robert J.
    Schabath, Matthew B.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (08):
  • [50] ERCC1 and personalized medicine in lung cancer
    Ryu, Jeong Seon
    Memon, Azra
    Lee, Seul-Ki
    ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (04)